AstraZeneca Beats Expectations, China Momentum Continues — Earnings Review

AstraZeneca PLC (AZN.LN) reported results for the third quarter on Thursday. Here's what we looked at:

SALES: The British drug maker said sales in the quarter totaled $6.41 billion, ahead of analyst forecasts of $6.13 billion.